Oppenheimer analyst Jeff Jones lowered the firm’s price target on Corvus Pharmaceuticals (CRVS) to $15 from $17 and keeps an Outperform rating on the shares. The firm notes the company reported Q2 results and provided an update on plans for soquelitnib across multiple indications. Oppenheimer models a $100M financing in 2026 to extend runway with model refinements.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals Reports Q2 2025 Progress and Financials
- Corvus Pharmaceuticals reports Q2 EPS (10c), consensus (12c)
- Corvus Pharmaceuticals’ Promising Study on Soquelitinib for Atopic Dermatitis
- Corvus announces IND application approved by CDE of China NMPA to start trial
- Corvus Pharmaceuticals Holds Annual Stockholders Meeting